SR One

SR One SR One was founded in 1985 as GSK's corporate venture arm and spun out as an independent firm in 2020. Fund I raised $500M (2020), followed by Fund II at $600M (2023). The focus is early-stage biotech. translating groundbreaking science into next-generation medicines. The firm operates from San Francisco and London with a trans-Atlantic presence. Notable portfolio companies include CRISPR Therapeutics, Principia Biopharma, Turning Point Therapeutics, Nkarta, and Hotspot Therapeutics. The